Search

Author/Creator Mathias, A.

1. SAT0149 EXPOSURE-RESPONSE RELATIONSHIPS FOR EFFICACY AND SAFETY OF FILGOTINIB AND ITS METABOLITE GS-829845 IN SUBJECTS WITH RHEUMATOID ARTHRITIS BASED ON PHASE 2 AND PHASE 3 STUDIES. (2nd June 2020)

Authors:
Meng, A.; Anderson, K.; Nelson, C.; Kirby, B.; Ni, L.; Chuang, S. M.; Kearney, B.; Mathias, A.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
1013
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. PB2096: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT BTK INHIBITOR FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA AND PRIMARY VITREORETINAL LYMPHOMA. (23rd June 2022)

Authors:
Soussain, C.; Grommes, C.; Ward, R.; Peterson, C.; Cravets, M.; Mathias, A.; Sosa, J.; Kirby, B.; Ding, Z.; Yusuf, I.; Rose, M.; Steinberg, M.; Tun, H.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1967
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. A phase 3b study of sofosbuvir plus ribavirin in treatment‐naive and treatment‐experienced Korean patients chronically infected with genotype 2 hepatitis C virus. Issue 5 (10th February 2016)

Authors:
Ahn, S. H.; Lim, Y. S.; Lee, K. S.; Paik, S. W.; Lee, Y. J.; Jeong, S. H.; Kim, J. H.; Yoon, S. K.; Yim, H. J.; Tak, W. Y.; Han, S. Y.; Yang, J. C.; Mo, H.; Mathias, A.; Han, L.; Knox, S. J.; Brainard, D. M.; Kim, Y. J.; Byun, K. S.; Kim, Y. S.
Journal:
Journal of viral hepatitis
Issue:
Volume 23:Issue 5(2016)
Page Start:
358
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV‐Uninfected female subjects. (24th June 2014)

Authors:
German, P.; Moorehead, L.; Pang, Phillip; Vimal, M.; Mathias, A.
Journal:
Journal of clinical pharmacology
Issue:
Volume 54:Number 11(2014:Nov.)
Page Start:
1290
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. All‐oral therapy with nucleotide inhibitors sofosbuvir and GS‐0938 for 14 days in treatment‐naive genotype 1 hepatitis C (NUCLEAR). Issue 10 (31st March 2013)

Authors:
Lawitz, E. J.; Rodriguez‐Torres, M.; Denning, J.; Mathias, A.; Mo, H.; Gao, B.; Cornpropst, M. T.; Berrey, M. M.; Symonds, W. T.
Journal:
Journal of viral hepatitis
Issue:
Volume 20:Issue 10(2013)
Page Start:
699
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗